# Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

> **NCT03658629** · PHASE2 · TERMINATED · sponsor: **Novavax** · enrollment: 1375 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** NanoFlu (Quad-NIV)
- **OTHER:** Matrix-M Adjuvant
- **OTHER:** Placebo
- **BIOLOGICAL:** Fluzone HD
- **BIOLOGICAL:** Flublok Quadrivalent
- **BIOLOGICAL:** Influenza Vaccine

## Key facts

- **NCT ID:** NCT03658629
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-24
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-04-26
- **Target enrollment:** 1375 (ACTUAL)
- **Why stopped:** This study was terminated 182 days after initial dosing.
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03658629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03658629, "Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03658629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*